The initial treatment results of 6 patients with non-small cell lung cancer with EGFR and ALK concurrent mutations, at National Lung Hospital

Evaluate the initial treatment results of non-small cell lung cancer with EGFR and ALK concurrent mutations. Subjects and methods: A prospective study, non-controlled description, and longitudinal follow-up of 6 patients with stage IIIB-IV non-small cell lung cancer, with EGFR and ALK concurrent mutations, at the National Lung Hospital, from January 2022 to July 2023.